Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

[1]  P. Sharma,et al.  Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy , 2019, Clinical Cancer Research.

[2]  J. Wolchok,et al.  DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). , 2017 .

[3]  M. Mahajan,et al.  Identification of a novel RASD1 somatic mutation in a USP8-mutated corticotroph adenoma , 2017, Cold Spring Harbor molecular case studies.

[4]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[5]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[6]  M. Berger,et al.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma , 2017, Clinical Cancer Research.

[7]  Sean C. Bendall,et al.  Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.

[8]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[9]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[10]  L. Garraway,et al.  Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.

[11]  I. Ostrovnaya,et al.  Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). , 2016 .

[12]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[13]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[14]  Roland L Dunbrack,et al.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.

[15]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[16]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[17]  Yusuke Nakamura,et al.  Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival , 2014, Clinical Cancer Research.

[18]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[19]  I. D. de Vries,et al.  Molecular Pathways Molecular Pathways : The Immunogenic Effects of Platinum-Based Chemotherapeutics , 2014 .

[20]  Maria Jure-Kunkel,et al.  Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models , 2013, Cancer Immunology, Immunotherapy.

[21]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[22]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[23]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Wolchok,et al.  Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.

[25]  A. Korman,et al.  Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy , 2010, Journal of immunotherapy.

[26]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[27]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[28]  L. Zitvogel,et al.  Immunogenic cancer cell death: a key-lock paradigm. , 2008, Current opinion in immunology.

[29]  G. Francini,et al.  Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs , 2008, Journal of immunotherapy.

[30]  J. Frelinger,et al.  Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.

[31]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. V. Rao,et al.  Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .

[33]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[34]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[35]  May,et al.  [Wiley Series in Probability and Statistics] Applied Survival Analysis (Regression Modeling of Time-to-Event Data) || Extensions of the Proportional Hazards Model , 2008 .